Global Coalition on Aging and Alzheimer’s Disease International Call on Countries to Foster Innovation in Dementia Treatment, Prevention, and Care as Global Prevalence Skyrockets

Dementia Innovation Readiness Index Issues Call-to-Action for Argentina, Brazil, China, India, and Saudi Arabia to Prioritize National Plans, Earlier Detection and Diagnosis, Quality Care, and Awareness Campaigns

(Chicago – July 27, 2018) – Today, the Global Coalition on Aging (GCOA) and Alzheimer’s Disease International (ADI) will present findings from the 2018 Dementia Innovation Readiness Index during ADI’s 33rd Conference at McCormick Place in Chicago. The Index analyzes – for the first time ever – the readiness of countries to develop and deploy dementia solutions into their healthcare, policy and social frameworks. This year’s Index evaluates Argentina, Brazil, China, India, and Saudi Arabia. On a 0-10 scale, with 10 being the highest in terms of innovation readiness, scores were as follows: Argentina – 5.3, Brazil – 5.0, China – 6.1, India – 5.1, and Saudi Arabia – 5.9.

Michael W. Hodin, PhD, CEO of GCOA said, “The Dementia Innovation Readiness Index provides leaders across these five countries a comprehensive look into the critical levers that lend to the facilitation of innovation in dementia prevention, treatment and care.

“Governments, NGOs, academia, and industry all have important roles to play as Alzheimer’s and other forms of dementia threaten to become the fiscal nightmare of the 21st century. Even in these countries with younger populations, preparation for the onslaught of dementia that comes with the aging of society cannot wait, and innovation is the key.”

The Index evaluates innovation readiness across 10 categories and identifies specific opportunities and challenges to promote innovation. Among the countries profiled this year, the 65+ population is highest in Argentina at 11.6% and lowest in Saudi Arabia at 3.3%. In comparison, 17.9% of the G7 countries’ population is over 65. And yet, developing countries will be home to nearly 70% of people with dementia by 2050 as the result of population aging.

Paola Barbarino, CEO of ADI said, “The projected increases in the prevalence of dementia around the world present massive health and financial challenges not only for governments and societies, but also individuals, families, and communities.

“People with dementia need early diagnosis, clear care pathways, access to skilled caregiving, and, most importantly, they need their voices to be heard. We encourage leaders in these five countries to use the Index as a wake-up call and roadmap for implementing dementia plans, developing comprehensive funding strategies for research, and raising awareness of dementia across the board.”

The Index found that, although Argentina, Brazil, China, India, and Saudi Arabia have younger populations than G7 countries, they face many of the same barriers to dementia innovation, including limited public leadership and funding, uneven access to high-quality care, and difficulty with early, accurate diagnosis. However, because of their relative youth, these countries lack focus on – and even recognition of – issues related to dementia. Further, the barriers to innovation are exacerbated by resource limitations including, in some cases, extreme poverty.

Huali Wang of the Peking University Institute of Mental Health, China said, “One challenge we must overcome in China is the wide variability in levels of care people receive based on where they live.

“While people living in certain urban areas receive high-quality care, those in rural areas and villages may struggle to receive timely diagnosis and appropriate care.”

The Index’s assessments of the five countries finds that only Argentina has a national dementia plan, which is a program led by Programa de Atención Médica Integral (PAMI) – the Argentine agency responsible for elder care. However, some regional and local areas with rapidly aging populations – such as Tucumán, Argentina, and Kerala, India – are taking the initiative to prioritize and respond to dementia, providing a possible model for larger-scale innovation.

Dr. Ricardo Allegri, Institute for Neurological Research (FLENI), Argentina said, “While it’s encouraging to see local efforts in Argentina, the country also needs a sustained commitment from the national government to promote dementia innovation – and the funds to back it up.”

Other key findings from the Index include:

  • Under-diagnosis is a barrier to fully understanding and treating dementia. Better diagnostic tools and healthcare professionals specializing in geriatrics and dementiawill be critical for ensuring countries can adequately address the individual and societal burden brought by Alzheimer’s and other dementias. In Brazil, for instance, community health workers are trained to identify signs of dementia and refer patients to specialists.
  • The regulatory environment has been slow to evolve with the urgency of the disease. Well-funded and efficient regulatory agencies must be prioritized to ensure therapiescan reach people with dementia in a timely manner.
  • The business community is not integrated into strategies to provide solutions for dementia and should be encouraged and incentivized to bring innovations in medicines and new care models, including maximizing the potential of technology and data.
  • As seen in India, prevention campaigns can serve as an effective and cost-efficient strategy to raise awareness and help the general public and healthcare providers better prepare for the projected increases in dementia.
  • Planning now will ensure these countries with younger populations are prepared for the coming demographic shift. For instance, Saudi Arabia, with currently only 3.3% of its population over 65, has a unique opportunity to innovate now so that in 20 years, solutions that lessen or eliminate the burden of dementia will already be in place.

Index findings are based on an expansive set of survey research, data analysis, and interviews with dozens of experts and representatives from each of the countries studied. These experts represent thousands of stakeholders in the fight against dementia and provide nuanced insights on both common themes and country-specific needs. This year’s Index expands on the first edition of the Index, published in 2017, which focused on G7 countries.

In addition, today GCOA and ADI released the Dementia Innovation Readiness Index: G7 Progress Report, highlighting notable progress since the initial Index was published last year. These developments include an unprecedented level of investment in dementia research by the U.S. government, a commitment from Canada to create a national dementia plan, and the launch of innovative workforce recruitment models in Germany and Japan.

“Policymakers should take a close look at both the 2018 Index and the G7 progress report. They go beyond reporting and provide clear, actionable steps to ensure that people with dementia and their families can get the support they deserve – today, tomorrow, and 10 years from now,” said Lenny Shallcross, Executive Director of the World Dementia Council. “These reports have essential information that can help leaders to design and implement real, powerful solutions for the oncoming dementia crisis.”

The 2018 Dementia Innovation Readiness Index and the G7 Progress Report will be presented today at 5:45 p.m. alongside a panel of experts at the 33rd Annual Alzheimer’s Disease International Conference in Chicago. Speakers will include:

  • Michael Hodin, PhD, CEO, Global Coalition on Aging
  • Chris Lynch, Policy, Communications and Publications Director and Deputy CEO, Alzheimer’s Disease International
  • Mary Alexander, Vice President of Strategic Partnerships and Healthcare Integration, Home Instead Senior Care
  • Ricardo Allegri, Institute for Neurological Research(FLENI)
  • Meera Pattabiraman, Chairperson, Alzheimer’s and Related Disorders Society of India
  • André Trottier, Senior International Health Policy Leader, Roche

The session is open to the media.

CONTACT

Melissa Mitchell Executive Director
Global Coalition on Aging
mmitchell@globalcoalitiononaging.com
+1 646 404 1149

Jake Hauritz
Alzheimer’s Disease International
jh@manacommunications.com
+61 478 128 268

Kate Elliott
Alzheimer’s Disease International
k.elliott@alz.co.uk
+00 44 7779 870982

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

What Old Age Might Be Like for Today’s 30-Year-Olds

Get ready for a new old age. With the U.S. fertility rate in a decadelong slump and the life expectancy of 65-year-old Americans approaching roughly 85, our aging nation is likely to grow older by midcentury, as the ratio of young to old continues to decline. The trend is likely to upend how our society is organized, making life very different for today’s 30-year-olds when they reach their 60s compared with life for 60-year-olds now.

World Population Reaches 8bn As It Grows Older

The world’s population reached 8bn people on Tuesday and will hit 9bn in 15 years as it experiences an unprecedented surge in the number of older people, according to the latest UN data. The global fertility rate has more than halved since the 1950s to 2.3 births per woman. With mortality also falling, the number of people aged 65 and over is expected to rise from 783mn in 2022 to 1bn by 2030 and reach 1.4bn by 2043, the UN population data revealed.

Global Coalition on Aging (GCOA) Launches Cross-Sector Alliance Committed to Health Innovation at High-Level Forum on The Silver Economy

Today, the Global Coalition on Aging (GCOA), along with cross-sector stakeholders representing patient advocacy, policy, industry, and academic communities, announced the launch of the Alliance for Health Innovation at the High-Level Forum on the Silver Economy in New York. The Alliance is dedicated to establishing the importance of innovation in achieving healthy aging and health equity through investments, policy reforms, and strategic partnerships.

Japan Must Face Up to Growing Danger of Drug-resistant Germs

In the wake of more than 6.4 million COVID-19 deaths worldwide and unprecedented economic destruction, the global community has no excuse to be caught unprepared for the next pandemic. Yet right now, a devastating parallel plague is already underway and worsening. Some years, it is killing well over 1 million people, according to medical journal The Lancet.

A Bipartisan Bill Could Prevent The Next Pandemic

In Washington, Republicans and Democrats are typically at loggerheads when it comes to healthcare policy. Just consider the recent Inflation Reduction Act, which made extensive changes to Medicare and also extended Affordable Care Act subsidies. Every single congressional Democrat voted for the legislation, while every single member of the GOP voted against it. But occasionally, a bill is such an obviously good idea, and so desperately needed, that it commands significant bipartisan support. The PASTEUR Act, co-sponsored by 31 Democrats and 31 Republicans in the House and two members of each party in the Senate, is just such a bill.

Korea Must Act Now to Combat Growing AMR Threat

Public officials are overlooking one of the gravest long-term threats to the Korean people, the health system, and economy: antimicrobial resistance (AMR). Some pathogens ― bacteria, fungi, parasites, and viruses ― have evolved strains that resist the antimicrobial medications we currently have available to fight them. Health care professionals often must watch helplessly as patients succumb to infections that antibiotics could once have easily beaten. They know that new antimicrobials, including and especially antibiotics, could easily gain the victory ― but they have none at their disposal.

Policy Statement on the Impact of Price Negotiations on Innovation, Healthy Aging and Equity

As the CEO of the Global Coalition on Aging (GCOA) and a newly formed cross-sector Alliance for Health Innovation, we write to express our deep concern with the current legislation that allows for price “negotiations” in Medicare – a thinly veiled signal for America’s plunge into price controls that will have a devastating and adverse impact on biopharmaceutical innovation and our nations’ ability to support healthy aging.